Pages that link to "Q37636344"

The following pages link to The unique role of proprotein convertase subtilisin/kexin 9 in cholesterol homeostasis (Q37636344):

Displaying 44 items.

• Subjects with Molecularly Defined Familial Hypercholesterolemia or Familial Defective apoB-100 Are Not Being Adequately Treated (Q28477200) (← links)
• Cholesterol, the central lipid of mammalian cells (Q34021021) (← links)
• A Highly Durable RNAi Therapeutic Inhibitor of PCSK9. (Q34047773) (← links)
• High-dose atorvastatin causes a rapid sustained increase in human serum PCSK9 and disrupts its correlation with LDL cholesterol (Q34053143) (← links)
• Novel domain interaction regulates secretion of proprotein convertase subtilisin/kexin type 9 (PCSK9) protein (Q34227474) (← links)
• PCSK9 is present in human cerebrospinal fluid and is maintained at remarkably constant concentrations throughout the course of the day. (Q34411560) (← links)
• Policosanol attenuates statin-induced increases in serum proprotein convertase subtilisin/kexin type 9 when combined with atorvastatin (Q34588435) (← links)
• Effects of currently prescribed LDL-C-lowering drugs on PCSK9 and implications for the next generation of LDL-C-lowering agents (Q34662589) (← links)
• Impacts of ezetimibe on PCSK9 in rats: study on the expression in different organs and the potential mechanisms (Q35194029) (← links)
• Novel method for reducing plasma cholesterol: a ligand replacement therapy (Q35558371) (← links)
• Serum proprotein convertase subtilisin/kexin type 9 and cell surface low-density lipoprotein receptor: evidence for a reciprocal regulation (Q37250324) (← links)
• Genetics of atherothrombosis and thrombophilia (Q37738343) (← links)
• PCSK9: an emerging target for treatment of hypercholesterolemia (Q37825903) (← links)
• The role of proprotein convertase subtilisin/kexin type 9 in hyperlipidemia: focus on therapeutic implications (Q37880856) (← links)
• Molecular pathology of familial hypercholesterolemia, related dyslipidemias and therapies beyond the statins (Q37972887) (← links)
• Pharmacogenomics of lipid-lowering therapies (Q38112823) (← links)
• Genetically modified pigs to model human diseases (Q38162792) (← links)
• Proprotein convertase subtilisin/kexin 9 inhibitors: an emerging lipid-lowering therapy? (Q38221015) (← links)
• Role of the C-terminal domain of PCSK9 in degradation of the LDL receptors (Q38415736) (← links)
• Update of Clinical Trials of Anti-PCSK9 Antibodies (Q38444379) (← links)
• Pleiotropic effects of antitumour alkylphospholipids on cholesterol transport and metabolism. (Q38808338) (← links)
• RNA therapeutics inactivate PCSK9 by inducing a unique intracellular retention form. (Q38897430) (← links)
• The increase in cholesterol levels at early stages after dengue virus infection correlates with an augment in LDL particle uptake and HMG-CoA reductase activity (Q39156568) (← links)
• Impact of Target-Mediated Elimination on the Dose and Regimen of Evolocumab, a Human Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9). (Q39175455) (← links)
• c-IAP1 binds and processes PCSK9 protein: linking the c-IAP1 in a TNF-α pathway to PCSK9-mediated LDLR degradation pathway (Q39255706) (← links)
• Effect of E670G Polymorphism in PCSK9 Gene on the Risk and Severity of Coronary Heart Disease and Ischemic Stroke in a Tunisian Cohort (Q39470591) (← links)
• PCSK9-mediated degradation of the LDL receptor generates a 17 kDa C-terminal LDL receptor fragment. (Q40470485) (← links)
• Investigation of highly expressed PCSK9 in atherosclerotic plaques and ox-LDL-induced endothelial cell apoptosis (Q42347016) (← links)
• Disrupted recycling of the low density lipoprotein receptor by PCSK9 is not mediated by residues of the cytoplasmic domain (Q42957646) (← links)
• Short-term impact of low-dose atorvastatin on serum proprotein convertase subtilisin/kexin type 9. (Q44811412) (← links)
• Familial hypercholesterolemia and atherosclerosis in cloned minipigs created by DNA transposition of a human PCSK9 gain-of-function mutant (Q44937777) (← links)
• Differences in allele frequencies of autosomal dominant hypercholesterolemia SNPs in the Malaysian population (Q46286854) (← links)
• Prevalence of cholesteryl ester storage disease among hypercholesterolemic subjects and functional characterization of mutations in the lysosomal acid lipase gene (Q49357663) (← links)
• Peripheral vascular atherosclerosis in a novel PCSK9 gain-of-function mutant Ossabaw miniature pig model (Q49634837) (← links)
• Decreased maternal and fetal cholesterol following maternal bococizumab (anti-PCSK9 monoclonal antibody) administration does not affect rat embryo-fetal development (Q50560684) (← links)
• Characterization of a naturally occurring degradation product of the LDL receptor (Q51763927) (← links)
• PCSK9: From Basic Science Discoveries to Clinical Trials. (Q54631590) (← links)
• All-in-one adeno-associated virus delivery and genome editing by Neisseria meningitidis Cas9 in vivo (Q58324031) (← links)
• Familial Hypercholesterolemia: The Most Frequent Cholesterol Metabolism Disorder Caused Disease (Q58555382) (← links)
• Serum levels of proprotein convertase subtilisin/kexin type 9 in subjects with familial hypercholesterolemia indicate that proprotein convertase subtilisin/kexin type 9 is cleared from plasma by low-density lipoprotein receptor-independent pathways (Q84343483) (← links)
• Affinity and kinetics of proprotein convertase subtilisin/kexin type 9 binding to low‐density lipoprotein receptors on HepG2 cells (Q84409159) (← links)
• Leucine 10 allelic variant in signal peptide of PCSK9 increases the LDL cholesterol-lowering effect of statins in patients with familial hypercholesterolaemia (Q84948794) (← links)
• Accumulation of Pericardial Fat Is Associated with Alterations in Heart Rate Variability Patterns in Hypercholesterolemic Pigs (Q90442919) (← links)
• Advances in oligonucleotide drug delivery (Q98386176) (← links)